Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Hepatocellular × durvalumab × Clear all

Phase

Status

Recruiting 29 Active not recruiting 16 Unknown 6 Not yet recruiting 5 Completed 5 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Breast Neoplasms 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Head and Neck Neoplasms 2 Carcinoma, Transitional Cell 2 Urothelial Cancer 1 Urinary Bladder Diseases 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thrombocytosis 1 Testicular Neoplasms 1 Solid Tumors 1 Solid Tumor 1

Interventions

Sorafenib 29 Nivolumab 15 pembrolizumab 12 Radiosurgery 9 Bevacizumab 9 atezolizumab 7 regorafenib 5 Radiotherapy 5 Fluorouracil 5 Doxorubicin 5 Sunitinib 4 Oxaliplatin 4 Ipilimumab 4 Gemcitabine 4 Ethiodized Oil 4 Erlotinib Hydrochloride 4 Capecitabine 4 lenvatinib 3 TLC 388 3 Radiofrequency Ablation 3 Leucovorin 3 Everolimus 3 Cisplatin 3 toripalimab 2 phosphomannopentaose sulfate 2 cediranib 2 avelumab 2 Tirapazamine 2 Panobinostat 2 Melphalan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡